Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study

Vikas Gupta, Martin Griesshammer, Bruno Martino, Lynda Foltz, Renato Tavares, Haifa Kathrin Al-Ali, Pilar Giraldo, Paola Guglielmelli, Elza Lomaia, Catherine Bouard, Carole Paley, Ranjan Tiwari, Evren Zor, Pia Raanani

Research output: Contribution to journalArticlepeer-review

Abstract

Data from the large, prospective, multinational, phase 3b JUMP study were analyzed to identify factors predictive of spleen and symptom responses in myelofibrosis patients receiving ruxolitinib. Factors associated with higher spleen response rates included International Prognostic Scoring System (IPSS) low/intermediate-1 risk vs intermediate-2/high risk (43.1% vs 30.6%; adjusted OR [aOR] 0.65 [95% CI 0.44–0.95]), ruxolitinib as first- vs second- or later-line therapy (40.2% vs 31.5%; aOR 0.53 [95% CI 0.38–0.75]), and a ruxolitinib total daily dose at Week 12 of >20 mg/day vs ≤20 mg/day (41.3% vs 30.4%; aOR 0.47 [95% CI 0.33–0.68]). No association was seen between baseline characteristics or total daily dose at Week 12 and symptom response. Ruxolitinib led to higher spleen response rates in patients with lower IPSS risk, and when used earlier in treatment. Higher doses of ruxolitinib were associated with higher spleen response rates, but not with symptom improvement.Trial registration INC424 for patients with primary myelofibrosis, post polycythemia myelofibrosis or post-essential thrombocythemia myelofibrosis (JUMP). 2010-024473-39; NCT01493414 Date of registration: 16 December 2011 https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024473-39https://clinicaltrials.gov/ct2/show/NCT01493414.

Original languageEnglish
Pages (from-to)918-926
Number of pages9
JournalLeukemia and Lymphoma
Volume62
Issue number4
DOIs
StatePublished - 2021

Keywords

  • Myelofibrosis
  • predictors
  • prognostic
  • ruxolitinib
  • splenomegaly

Fingerprint

Dive into the research topics of 'Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study'. Together they form a unique fingerprint.

Cite this